KRAS-specific autologous TCR-T cell therapy

· Corregene Biotechnology Co., Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KRAS-specific autologous TCR-T cell therapy, covering 2026-03-25 to 2026-03-25. Get the full timeline:

Most recent: Clinical Trial Update: KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors [Phase 1]